Partnering for Progress: How Astellas and the Pompe Disease Community Are Shaping the Future Together Pompe disease is a rare, inherited, and progressively debilitating disorder that profoundly affects the lives of those diagnosed with it, as well as their families…
Practice-Changing Data, Innovative Modalities, and Global Impact Headline ASCO 2025 The oncology community is converging in Chicago this week for the highly anticipated 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), with excitement mounting over groundbreaking research…
U.S. Vaccine Innovation at Risk: How Four Biotechs Are Being Squeezed by Shifting Policies, Funding Cuts, and Regulatory Changes As the World Health Organization (WHO) sets a new course for global pandemic preparedness, efforts to develop next-generation COVID-19 vaccines in…
World Health Assembly Approves Extension of Global Digital Health Strategy to 2027 and Greenlights Next Phase for 2028–2033 In a landmark decision underscoring the accelerating global commitment to digital health, Member States at the Seventy-eighth World Health Assembly (WHA78) have…
Astellas and Pfizer Showcase Five-Year Survival Benefits of XTANDI in Metastatic Hormone-Sensitive Prostate Cancer at ASCO 2025 In a pivotal milestone for prostate cancer treatment, Astellas Pharma Inc. and Pfizer Inc. have announced compelling long-term survival data for XTANDI™ (enzalutamide),…
Bringing Research to the People: How Walgreens Clinical Trials is Revolutionizing Patient Engagement Over the past three years, Walgreens has made remarkable strides in democratizing access to clinical trials. Through its innovative and community-centered approach, the company has reached more…
Federal Judge Blocks Trump Administration’s Sweeping HHS Layoff and Reorganization Plan, Citing Lack of Legal Authority A federal judge in California has issued a significant legal blow to the Trump administration’s effort to fundamentally restructure and shrink the U.S. Department…
Bayer’s Eylea™ 8 mg Recommended for EU Approval with Extended 6-Month Treatment Interval for Major Retinal Diseases Bayer has today announced a significant milestone in the treatment of retinal diseases, revealing that the Committee for Medicinal Products for Human Use…
GSK’s Blenrep Combinations Receive Positive CHMP Opinion for Relapsed or Refractory Multiple Myeloma, Signaling Expanded Access Across Europe In a significant step forward for the treatment of multiple myeloma, GSK plc (LSE/NYSE: GSK) has announced that the Committee for Medicinal…
NICE Recommends FILSPARI® (sparsentan) for Routine Use in the NHS to Treat Adults with IgA Nephropathy, Marking a Significant Step Forward in Rare Kidney Disease Management CSL Vifor has announced a major regulatory and reimbursement milestone for its innovative kidney…
Rethinking Nicotine: CVS Health Survey Uncovers Widespread Misconceptions About E-Cigarette Safety Among Young Adults Over the past few decades, the public conversation around tobacco and nicotine use has transformed dramatically. Once glamorized in movies, magazines, and advertisements, cigarette smoking has…
Trodelvy Marks Breakthrough in First-Line mTNBC Treatment with Positive Phase 3 ASCENT-03 Results Gilead Sciences has announced encouraging topline results from its Phase 3 ASCENT-03 clinical trial evaluating Trodelvy® (sacituzumab govitecan-hziy) in a particularly challenging patient population: individuals newly diagnosed…